Tumor-suppressing viruses, genes, and drugs : innovative cancer therapy approaches / edited by Hiroshi Maruta.

Format:

Book

Contributor:

Maruta, Hiroshi.

Language:

English

Subjects (All):

Antioncogenes.

Cancer--Gene therapy.

Cancer.

Viruses--Therapeutic use.

Viruses.

Cancer--Treatment--Technological innovations.

Cancer--Molecular aspects.

Physical Description:

1 online resource (441 p.)

Place of Publication:

San Diego : Academic Press, c2002.

Language Note:

English

Summary:

Tumor Suppressing Viruses, Genes, and Drugs profiles the new generation of cancer treatments now in development. The book examines the innovative new approaches of viral, gene, and signal therapies that promise to replace or enhance conventional methods such as surgery, radiation, and chemotherapy. The timely information presented by this book should be of interest to anyone concerned with advancing cancer treatment beyond current medical practices.

Contents:

Front Cover; Tumor-Suppressing Viruses, Genes, and Drugs; Copyright; Contents; Contributors; Preface; Chapter 1. Oncolytic Viruses: Virotherapy for Cancer; I. Introduction; II. Attributes of Replication-Selective Viruses for Cancer Treatment; III. Approaches to Optimizing Tumor-Selective Viral Replication; IV. Adenoviruses; V. Poliovirus; VI. Vesicular Stomatitis Virus; VII. Reovirus; VIII. Bacteria; IX. Vaccinia Virus; X. Herpesvirus; XI. Clinical Trial Results with Replication-Competent Adenoviruses in Cancer Patients; XII. Results from Clinical Trials with dl1520 (Onyx-015, or CI-1042)

XIII. Future Directions: Approaches to Improving the Efficacy of Replication-Selective Viral AgentsXIV. Summary; References; Chapter 2. Reovirus Therapy of Ras-Associated Cancers; I. Introduction; II. Reovirus Oncolysis; III. Concluding Remarks; References; Chapter 3. Oncolytic Herpes Simplex Virus (G207) Therapy: From Basic to Clinical; I. Introduction; II. Preclinical Studies of G207; III. G207 Clinical Trial; IV. Conclusions; References; Chapter 4. p53 and Its Targets; I. Introduction; II. Activation of p53; III. Downstream Mediators of p53; References

Chapter 5. Prospects for Tumor Suppressor Gene Therapy: RB as an ExampleI. Introduction; II. Functions of RB; III. Successes with RB Gene Therapy; IV. Perspectives; References; Chapter 6. CDK Inhibitors: Genes and Drugs; I. Introduction; II. G1 Regulation; III. p16INK4a and the Rb Pathway; IV. p19ARF and p53 Pathway; V. p27 and Human Cancer; VI. Conclusions and Future Perspectives; References; Chapter 7. CDK Inhibitors: Small Molecular Weight Compounds; I. Introduction; II. Cyclin-Dependent Kinases, the Cell Cycle, and Cancer

III. Cyclin-Dependent Kinase Inhibitors, a Large Variety of StructuresIV. Cyclin-Dependent Kinase Inhibitors, All Competing with ATP; V. Cyclin-Dependent Kinase Inhibitors, the Selectivity Problem; VI. Cyclin-Dependent Kinase Inhibitors, Cellular Effects; VII. Cyclin-Dependent Kinase Inhibitors, Antitumor Activity; VIII. Conclusion; References; Chapter 8. NF1 and Other RAS-Binding Peptides; I. RAS Molecules: Normal versus Oncogenic Mutants; II. Super GAP?; III. RAS-Binding Fragment of NF1; IV. c-RAF-1; V. PI-3 Kinase; VI. Ral GDS; References; Chapter 9. Cytoskeletal Tumor Suppressor Genes

I. Introduction (Historical Background)II. Type I Cytoskeletal Tumor Suppressors; III. Type II Cytoskeletal Tumor Suppressors; References; Chapter 10. TGF-ß Signaling and Carcinogenesis; I. Introduction; II. Dual Role of TGF-ß in Carcinogenesis; III. TGF-ß Superfamily Signaling; IV. Perturbation of TGF-ß Signaling in Cancer Cells; V. Perspectives; References; Chapter 11. DAN Gene; I. Introduction; II. Cloning of DAN cDNA; III. Transfection of DAN; IV. Role of DAN in Neuroblastomas; V. Structural Features of the DAN Protein; VI. Genomic Structure of DAN; VII. DAN Family; References

Chapter 12. Design of Hammerhead Ribozymes and Allosterically Controllable Maxizymes for Cancer Gene Therapy

Notes:

Description based upon print version of record.

Includes bibliographical references and index.

ISBN:

1-281-11923-7

9786611119232

0-08-054902-0

OCLC:

476084062